These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12006542)

  • 1. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
    Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
    Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
    Uckun F; Dibirdik I; Sarkissian A; Qazi S
    Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
    Cetkovic-Cvrlje M; Uckun FM
    Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
    Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
    Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
    van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
    Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
    Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
    Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
    Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
    DuMez D; Venkatachalam TK; Uckun FM
    Arzneimittelforschung; 2007; 57(3):155-63. PubMed ID: 17469650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
    Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
    Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.
    Uckun FM
    Cell Cycle; 2007 Dec; 6(24):3021-6. PubMed ID: 18073537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
    Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases.
    Fernandes MJ; Lachance G; Paré G; Rollet-Labelle E; Naccache PH
    J Leukoc Biol; 2005 Aug; 78(2):524-32. PubMed ID: 15899983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Pawlak K; Czarnomysy R; Bielawski K; Prokop I; Pawlak D
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice.
    Meng Y; Sha S; Yang J; Ren H
    Dig Dis Sci; 2019 Aug; 64(8):2167-2176. PubMed ID: 30761473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration.
    Zen K; Liu Y
    Immunobiology; 2008; 213(1):13-23. PubMed ID: 18207024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.